Lygature on the impact of multi-stakeholder Public-Private Partnerships
In recent years Public-Private Partnerships (PPPs) have evolved into broader coalitions. Health foundations, patient organizations and even regulatory agencies have taken an active role in PPPs. Indicators that measure the impact of such precompetitive research collaborations in the biomedical field have been developed. Tangible outcomes are identified for four case studies (IMI, SGC, TI Pharma & ADNI).
Public-Private Partnerships are multilateral stakeholder partnerships designed to improve research efficacy. In the expert review published in Pharmaceutical Research, De Vrueh and Crommelin focus on PPPs in the pharmaceutical field. Over the last 25 years pharmaceutical companies have adopted open innovation and therewith increased their engagement with universities. At the same time universities have made research valorization an integral part of their mission. Originally, a typical PPP was based on an academic and an industrial partner, with government funding as an incentive. Over time, other stakeholders, such as health foundations, patient organizations, and regulatory bodies have joined the ranks.
The review discusses reasons for initiating a PPP, focusing on precompetitive research. It looks at typical expectations and challenges when starting such an endeavour, the characteristics of PPPs, and approaches to assessing the success of the concept. Finally, four case studies are presented of PPPs differing in size, geographical spread, and research focus. De Vrueh and Crommelin show that PPPs generate tangible outcomes with the potential to positively impact clinical application and eventually, medical practice.
Pharmaceutical R&D is complex and characterized by lengthy timelines, and one could easily argue that these challenges make it very difficult to properly assess the long-term impact of the PPP concept on medical practice. However, we should continue to improve the metrics. Given the growing number of PPPs, the availability of funding and resources will become a limiting factor, and will “force” stakeholders to become even more prudent in selecting which PPP initiatives to back or join, and which ones to avoid. In simple terms, partners, funders, and civil society will increasingly seek confirmation of the substantial value achieved through partnerships.
The review, entitled “Reflections on the future of pharmaceutical Public-Private Partnerships: from input to impact,” is available (open access) on the Pharmaceutical Research journal website.
Source: Lygature